InterCure (INCR) Competitors

InterCure (NASDAQ:INCR) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Which has more risk and volatility, INCR or IMMP?

InterCure has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Immutep has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.

Does the media refer more to INCR or IMMP?

In the previous week, InterCure had 3 more articles in the media than Immutep. MarketBeat recorded 5 mentions for InterCure and 2 mentions for Immutep. Immutep's average media sentiment score of 0.94 beat InterCure's score of 0.71 indicating that Immutep is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immutep	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer INCR or IMMP?

Immutep has a consensus target price of $7.00, suggesting a potential upside of 280.43%. Given Immutep's stronger consensus rating and higher probable upside, analysts plainly believe Immutep is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Immutep	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor INCR or IMMP?

Immutep received 309 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 72.22% of users gave Immutep an outperform vote.

Company	Underperform	Outperform
InterCure	Outperform Votes 3 100.00%	Underperform Votes No Votes
Immutep	Outperform Votes 312 72.22%	Underperform Votes 120 27.78%

Is INCR or IMMP more profitable?

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Immutep	N/A	N/A	N/A

Which has preferable earnings & valuation, INCR or IMMP?

InterCure has higher revenue and earnings than Immutep.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$238.85M	0.29	-$16.83M	N/A	N/A
Immutep	$5.14M	52.28	-$28.01M	N/A	N/A

Do institutionals & insiders hold more shares of INCR or IMMP?

8.3% of InterCure shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 3.1% of Immutep shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Immutep beats InterCure on 8 of the 13 factors compared between the two stocks.